Document is current
Any future updates will be listed below
-
Authors
Nagata, Tetsuya
Dwyer, Chrissa A.
Yoshida-Tanaka, Kie
Ihara, Kensuke
Ohyagi, Masaki https://orcid.org/0000-0002-6009-450X
Kaburagi, Hidetoshi
Miyata, Haruka
Ebihara, Satoe
Yoshioka, Kotaro https://orcid.org/0000-0001-7094-9017
Ishii, Takashi
Miyata, Kanjiro https://orcid.org/0000-0001-7044-190X
Miyata, Kenichi
Powers, Berit
Igari, Tomoko
Yamamoto, Syunsuke
Arimura, Naoto
Hirabayashi, Hideki
Uchihara, Toshiki
Hara, Rintaro Iwata https://orcid.org/0000-0003-2399-3431
Wada, Takeshi
Bennett, C. Frank https://orcid.org/0000-0001-9887-6251
Seth, Punit P.
Rigo, Frank
Yokota, Takanori https://orcid.org/0000-0002-6490-3263
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (20am0401006h0002, 19ek0610013h0003, 19ek0610013h0003)
MEXT | Japan Society for the Promotion of Science (17H06109, 19H01016, 17H06109, 19H01016)
MEXT | Japan Science and Technology Agency (JPMJCR12L4)
- License Information
-
More Information
Article History
Received: 22 September 2020
Accepted: 2 June 2021
First Online: 12 August 2021
Competing interests
: T.Y. is collaborating with Daiichi Sankyo Co., Ltd. (Tokyo, Japan), Mitsubishi Tanabe Pharma Corporation (Osaka, Japan), NanoCarrier Co., Ltd. (Chiba, Japan), Ono Pharmaceutical Co., Ltd. (Osaka, Japan), Rena Therapeutics Inc. (Tokyo, Japan), Takeda Pharmaceutical Co., Ltd. (Tokyo, Japan) and Toray Industries, Inc. (Tokyo, Japan) and Ionis Pharmaceuticals (CA, USA). T.Y. also serves as academic adviser for Rena Therapeutics Inc. C.A.D., B.P., C.F.B., P.P.S. and F.R. are paid employees of Ionis Pharmaceuticals, Inc. Kenichi Miyata, T. Igari, S.Y., N.A. and H.H. are paid employees of Takeda Pharmaceutical Company Limited. T.Y. and T.N. are inventors on patents on BBB-HDO filed by Tokyo Medical and Dental University and have benefits from licensing of the associated intellectual property.
